Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
Sep 25, 2018 12:00 PM EDT
Antivirals: Targeting HBV and Beyond
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “Using siRNA to target the HBV transcriptome”
Archived Events
Date Event Details
Sep 16, 2018 12:15 PM CDT
European Respiratory Society International Congress 2018
September 16, 12:15 p.m. CEST – Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled, Targeting ENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”
Sep 7, 2018 5:45 PM EDT
18th World Gastroenterologists Summit
September 7, 09:45 a.m. NZST – Dr. Given will deliver a keynote presentation titled, “Hepatitis B in focus: New biology, new targets and real hope for finite therapy”
Sep 4, 2018
Annual B. Riley FBR Healthcare Conference
Bruce Given, M.D., Arrowhead’s chief operating officer, and Vincent Anzalone, CFA, vice president of investor relations, will participate in three panel discussions
Aug 7, 2018 4:30 PM EDT
Arrowhead Fiscal 2018 Third Quarter Results
Jun 29, 2018 3:45 PM PDT
27th Annual Alpha-1 National Education Conference
San Francisco, CA
Bruce Given, M.D., will deliver an oral presentation titled, “Development of ARO-AAT, an RNAi based therapeutic for Alpha-1 antitrypsin deficiency-related liver disease”
Jun 20, 2018 9:00 AM EDT
JMP Securities Life Science Conference
New York, NY
Bruce Given, M.D., will present a corporate overview
Jun 15, 2018 2:15 PM EDT
Global Hepatitis Summit 2018
Toronto
Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver an oral presentation titled, “Interferon-gamma pathway is activated in a chronically HBV infected chimpanzee that controls HBV following ARC-520 RNAi treatment”
Jun 8, 2018 5:30 PM +08
The Science of HBV Cure 2018
Suntec City, Singapore
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “Hitting HBV everywhere; why RNAi holds so much potential as a platform therapy in CHB”
Jun 6, 2018 3:30 PM EDT
Jefferies 2018 Global Healthcare Conference
New York, NY
Chris Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will present a corporate overview
Jun 6, 2018 5:55 PM CEST
41st European Cystic Fibrosis Conference
Belgrade, Serbia
Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled,“Targeting aENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”
May 21, 2018 9:15 AM PDT
American Thoracic Society (ATS) 2018 International Conference
San Diego
May 10, 2018 4:15 PM PDT
Vascular Discovery: From Genes to Medicine – Scientific Sessions 2018
San Francisco
May 8, 2018 4:30 PM EDT
Arrowhead Fiscal 2018 Second Quarter Results
Apr 25, 2018 4:00 PM EDT
World Orphan Drug Congress USA 2018
Apr 12 - Apr 14, 2018
The EASL International Liver Congress™ 2018

Oral Presentations:

Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection

  • Presentation Reference: PS-030
  • Session: Parallel session: Parallel session: HBV Cure: Pre-clinical studies
  • Date and Time: April 12, 2018 at 5:15 p.m. CET
  • Authors: Christine Wooddell, et al.

ARO-AAT, a subcutaneous RNAi-based therapeutic for alpha-1 antitrypsin-related liver disease, demonstrates liver exposure-response and efficacy in preclinical studies

  • Presentation Reference: PS-147
  • Session: Parallel session: Clinical developments in metabolic and rare disease
  • Date and Time: April 14, 2018 at 9:15 a.m. CET
  • Authors: Christine Wooddell, et al.

Poster Presentation:

RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV

  • Presentation Reference: FRI-362
  • Session: Viral hepatitis B/D: Therapy
  • Session Date and Time: April 13, 2018 from 9 a.m. to 5 p.m. CET
  • Authors: Man-Fung Yuen, et al.
Mar 29, 2018
American Society for Clinical Pharmacology & Therapeutics 2018 Annual Meeting
Mar 22, 2018
American Society for Clinical Pharmacology & Therapeutics 2018 Annual Meeting
Mar 13, 2018 1:35 PM EDT
Barclays Global Healthcare Conference 2018
Miami
Feb 27 - Mar 1, 2018 12:00 AM EST
AsiaTIDES: Oligonucleotide and Peptide Therapeutics
Kyoto, Japan
Feb 22, 2018 3:10 PM UTC
SMI RNA Therapeutics Conference
London
Feb 9, 2018 4:30 PM EST
Arrowhead Fiscal 2018 First Quarter Results
Jan 8 - Jan 10, 2018 12:00 AM EST
JP Morgan Healthcare Conference Week
Dec 12, 2017 4:30 PM EST
Arrowhead Pharmaceuticals 2017 Fiscal Year End Results
Dec 5, 2017 6:10 PM HST
HEP DART 2017
Kona, Hawaii
Nov 28, 2017 9:30 AM EST
29th Annual Piper Jaffray Healthcare Conference
Nov 13 - Nov 15, 2017 12:00 AM EST
BIT's 8th World Gene Convention-2017
Macau, China
Oct 23, 2017
The Liver Meeting® 2017, the Annual Meeting of the American Association for the Study of Liver Disease
Washington, DC

Subcutaneous delivery of a RNA interference (RNAi) therapeutic candidate for alpha-1 antitrypsin deficiency (AATD)-related liver disease produces deep and prolonged knockdown of plasma AAT

  • Publication Number: LB-21
  • Session: Late-Breaking Poster Session
  • Session Date and Time: October 23, 2017 from 8:00 AM to 5:30 PM

·        Authors: Christine I. Wooddell, et al.

Oct 10, 2017 10:45 AM EDT
Chardan Gene Therapy Conference
Sep 25, 2017 9:10 AM EDT
2017 Cantor Fitzgerald Global Healthcare Conference
Sep 14, 2017 1:00 PM EDT
Arrowhead Analyst R&D Day
Aug 3, 2017 4:30 PM EDT
Arrowhead Fiscal 2017 Third Quarter Results
May 5, 2017 11:30 AM CDT
Arteriosclerosis, Thrombosis and Vascular Biology | Peripheral Vascular Disease (ATVB|PVD) 2017 Scientific Sessions

Location: Minneapolis, MN

Title: Factor 12 RNAi-based therapeutic as a prophylactic anti-thrombotic therapy

May 3, 2017 4:30 PM EDT
Arrowhead Fiscal 2017 Second Quarter Results
Apr 19 - Apr 23, 2017 12:00 AM EDT
The EASL International Liver Congress™ 2017
Amsterdam, The Netherlands

Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen

  • Presentation Reference: PS-045
  • Session: Parallel session: Hepatitis B and D: Emerging treatment options
  • Date and Time: April 20, 2017 at 5:30 PM CET
  • Authors: Man-Fung Yuen, et al.

A phase 1 study to evaluate safety and tolerability of escalating single doses of the HBV RNA interference drug ARC-521 in a healthy volunteer population

  • Presentation Reference: THU-176
  • Session: Viral hepatitis: Hepatitis B and D - Clinical (therapy, new compounds, resistance)
  • Session Date and Time: April 20, 2017 from 8:00 AM to 6:00 PM CET
  • Authors: Edward Gane, et al.

Hepatic targeted RNA interference provides deep and prolonged knockdown of alpha-1 antitrypsin levels in ZZ patients

  • Presentation Reference: LBO-06
  • Session: Late Breaker session
  • Date and Time: April 22, 2017 at 5:15 PM CET
  • Authors: Alice Turner, et al.
Feb 21 - Feb 23, 2017 12:00 AM EST
AsiaTIDES: Oligonucleotide and Peptide Therapeutics
Kyoto, Japan
Feb 6, 2017 4:30 PM EST
Arrowhead Fiscal 2017 First Quarter Results
Dec 14, 2016 4:30 PM EST
Arrowhead Fiscal 2016 Year End Results
Nov 30, 2016 8:30 AM EST
The 28th Annual Piper Jaffray Healthcare Conference
New York

November 30, 8:30 a.m. EST – Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate overview in a fireside chat with Ted Tenthoff, senior research analyst, Piper Jaffray.

Presentation Canceled

Nov 29, 2016 4:30 PM EST
Clinical Update Call
Nov 14, 2016 10:00 AM CST
American Heart Association's Scientific Sessions 2016
New Orleans

November 14, 10:40 a.m. CST – Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, “Targeting factor XII (F12) with a novel RNAi delivery platform as a prophylactic treatment for thromboembolism”

November 14, 2:00 p.m. CST – Stacey Melquist, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, “Targeting apolipoprotein(a) with a novel RNAi delivery platform as a prophylactic treatment to reduce risk of cardiovascular events in individuals with elevated lipoprotein (a)”

Nov 13, 2016
The Liver Meeting® 2016, the Annual Meeting of the American Association for the Study of Liver Disease
Boston

RNA interference therapeutic ARC-AAT prevents production of Z-alpha1 antitrypsin polymers and reverses liver disease phenotype in PiZ mouse model

  • Publication Number: 124
  • Session: Parallel 19: Pediatric and Metabolic Liver Diseases: Basic and Translational
  • Session Date and Time: November 13, 2016 from 4:45 PM to 6:15 PM
  • Authors: Christine Wooddell, et al.

RNA interference (RNAi) with ARC-AAT provides deep and prolonged knockdown of alpha-1 antitrypsin levels in healthy volunteers

  • Publication Number: LB-24
  • Session: Late-Breaking Poster Session
  • Session Date and Time: November 13, 2016 from 8:00 AM to 5:30 PM

Authors: Alice Turner, et al.